Investors with a lot of money to spend have taken a bearish stance on Teva Pharmaceutical Indus TEVA.
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TEVA, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 8 uncommon options trades for Teva Pharmaceutical Indus.
This isn't normal.
The overall sentiment of these big-money traders is split between 12% bullish and 50%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $288,604, and 2 are calls, for a total amount of $143,091.
Projected Price Targets
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $17.0 for Teva Pharmaceutical Indus during the past quarter.
Insights into Volume & Open Interest
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Teva Pharmaceutical Indus's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Teva Pharmaceutical Indus's whale trades within a strike price range from $15.0 to $17.0 in the last 30 days.
Teva Pharmaceutical Indus 30-Day Option Volume & Interest Snapshot
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TEVA | CALL | SWEEP | BEARISH | 09/19/25 | $3.15 | $3.05 | $3.05 | $15.00 | $91.2K | 1.2K | 301 |
| TEVA | PUT | SWEEP | BEARISH | 01/16/26 | $2.16 | $2.06 | $2.16 | $17.00 | $76.8K | 10.7K | 611 |
| TEVA | PUT | SWEEP | BEARISH | 01/16/26 | $1.28 | $1.07 | $1.28 | $15.00 | $74.2K | 2.4K | 592 |
| TEVA | CALL | SWEEP | BEARISH | 02/21/25 | $0.52 | $0.4 | $0.51 | $16.50 | $51.8K | 1.2K | 1.0K |
| TEVA | PUT | TRADE | NEUTRAL | 06/20/25 | $1.45 | $1.38 | $1.42 | $17.00 | $35.5K | 15.3K | 250 |
About Teva Pharmaceutical Indus
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
In light of the recent options history for Teva Pharmaceutical Indus, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Where Is Teva Pharmaceutical Indus Standing Right Now?
- With a volume of 4,482,422, the price of TEVA is down -0.68% at $16.71.
- RSI indicators hint that the underlying stock may be oversold.
- Next earnings are expected to be released in 86 days.
Expert Opinions on Teva Pharmaceutical Indus
In the last month, 4 experts released ratings on this stock with an average target price of $28.25.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Teva Pharmaceutical Indus, targeting a price of $27. * An analyst from Piper Sandler persists with their Overweight rating on Teva Pharmaceutical Indus, maintaining a target price of $30. * An analyst from Barclays persists with their Overweight rating on Teva Pharmaceutical Indus, maintaining a target price of $26. * An analyst from UBS has decided to maintain their Buy rating on Teva Pharmaceutical Indus, which currently sits at a price target of $30.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Teva Pharmaceutical Indus options trades with real-time alerts from Benzinga Pro.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
